Compare CVS Health Corp (CVS) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Lululemon Athletica Inc — how do they compare? CVS Health Corp trades at $106.29 (market cap $135.48B), while Lululemon Athletica Inc trades at $116.94 (market cap $13.32B). The key difference: CVS Health Corp is far larger — about 10.2× Lululemon Athletica Inc's market cap, and CVS Health Corp pays a 2.51% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals.
| CVS | LULU | |
|---|---|---|
Market Cap | $135.48B | $13.32B |
Sector | Health | Consumer Cyclical |
52-Week High | $106.18 | $233.31 |
52-Week Low | $58.75 | $105.43 |
Enterprise Value | $202.02B | $13.94B |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Lululemon (LULU) trades at $120.30, up 0.87% today, showing resilience amid a challenging year. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Fundamentals remain strong with a 17.13% net margin and 32.03% ROE in 2025, though revenue growth is moderating. Technical indicators signal a bullish bias, with the current price near pivot point support at $121. Recent news highlights board stability after a proxy settlement but also ongoing brand controversies.
The outlook is cautiously optimistic. Valuation appears attractive with a P/E of 9.74, below sector averages, and a consensus price target of $130.53 implies upside. Key risks include North American sales weakness, intense competition, and potential brand damage from recent controversies. Earnings execution and international expansion are critical for a sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
